

Douglas Joshua

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10532988/publications.pdf>

Version: 2024-02-01

35
papers

2,783
citations

471061

17
h-index

395343

33
g-index

35
all docs

35
docs citations

35
times ranked

3600
citing authors

#	ARTICLE	IF	CITATIONS
1	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	5.1	723
2	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
3	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	5.1	320
4	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	0.8	294
5	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
6	CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. <i>Blood</i> , 2012, 120, 2055-2063.	0.6	82
7	Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 2761-2766.	0.8	76
8	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 484-497.	1.1	66
9	Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. <i>Leukemia and Lymphoma</i> , 2014, 55, 1090-1098.	0.6	66
10	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 149-159.	1.1	43
11	The T Cell in Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 537-542.	0.2	43
12	A CD2 high expressing stress resistant human plasmacytoid dendritic cell subset. <i>Immunology and Cell Biology</i> , 2016, 94, 447-457.	1.0	34
13	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	0.6	27
14	A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 37.	2.8	24
15	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	0.6	22
16	Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. <i>Oncolmmunology</i> , 2012, 1, 1658-1660.	2.1	21
17	The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with Myeloma. <i>Leukemia and Lymphoma</i> , 1991, 5, 151-155.	0.6	19
18	Mass Cytometry Discovers Two Discrete Subsets of CD39 ^{hi} Treg Which Discriminate MGUS From Multiple Myeloma. <i>Frontiers in Immunology</i> , 2019, 10, 1596.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Inverse relationship between oligoclonal expanded CD69 ⁺ TTE and CD69 ⁺ TTE cells in bone marrow of multiple myeloma patients. <i>Blood Advances</i> , 2020, 4, 4593-4604.	2.5	16
20	CD23 ANTIGEN EXPRESSION IN CLL. <i>British Journal of Haematology</i> , 1989, 72, 598-598.	1.2	13
21	Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2122-2133.	0.6	12
22	Quality of Patient-Centered Care Provided to Patients Attending Hematological Cancer Treatment Centers. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 549.	1.2	8
23	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	0.6	8
24	PERIPHERAL BLOOD LYMPHOCYTE SUBSETS AND NATURAL KILLER CELL NUMBER AND FUNCTION DURING Î±-INTERFERON TREATMENT FOR HAIRY CELL LEUKEMIA. <i>Australian and New Zealand Journal of Medicine</i> , 1988, 18, 897-899.	0.5	6
25	Carfilzomib+dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1364-1374.	0.6	6
26	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	0.6	5
27	Multiple Myeloma: Challenges and Opportunities. , 2005, 113, 1-4.		4
28	An Oral Iron Chelator and Quality of Life.. <i>Blood</i> , 2005, 106, 5553-5553.	0.6	4
29	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015, 126, 729-729.	0.6	3
30	Clonal Expansions of Cytotoxic T Cells in the Blood of Patients with Waldenstrom's Macroglobulinaemia Are Anergic and Disappear After Nucleoside Analogue Therapy.. <i>Blood</i> , 2009, 114, 1820-1820.	0.6	3
31	Alcohol and tobacco use and risk of multiple myeloma: A case-control study. <i>EJHaem</i> , 2022, 3, 109-120.	0.4	3
32	Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifyingFGFR3up-regulation. <i>Leukemia and Lymphoma</i> , 2015, 56, 2714-2716.	0.6	2
33	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.5	1
34	Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines. <i>Blood</i> , 2008, 112, 2639-2639.	0.6	1
35	Multiple Myeloma Surveillance Counterpoint: Australia. , 2013, , 493-500.		0